GlassScriptPhysician profile
Kellee D Frogge
NPI 1467434928
$1,701.20
in general payments reported to CMS, 2019-2025
25 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $60.72 · 2022: $87.03 · 2023: $418 · 2024: $378 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $318.69 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $239.42 | 2023-2025 | |
| Lilly USA, LLC | $170.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $131.50 | 2019-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $119.10 | 2019-2025 | Trintellix |
| Pfizer INC. | $82.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $64.06 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Astellas Pharma US INC | $62.11 | 2019-2024 | Veozah, Myrbetriq |
| Allergan, INC. | $59.52 | 2019-2020 | |
| Axsome Therapeutics, INC. | $55.30 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $45.47 | 2024-2025 | Rexulti |
| Glaxosmithkline, LLC. | $42.16 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Shield Therapeutics INC | $40.78 | 2024 | |
| Idorsia Pharmaceuticals US INC | $34.51 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $33.49 | 2023-2024 | Gemtesa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $29.23 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.48 | 2023-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $25.32 | 2022 | |
| Janssen Pharmaceuticals, INC | $23.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.13 | 2019 | |
| Merck Sharp & Dohme LLC | $17.13 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.81 | 2024 | Voquezna |
| Supernus Pharmaceuticals, INC. | $15.77 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.33 | 2023 | |
| Vanda Pharmaceuticals INC. | $15.29 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellee Frogge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.